These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 15857116)
1. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities. Wang GT; Li G; Mantei RA; Chen Z; Kovar P; Gu W; Xiao Z; Zhang H; Sham HL; Sowin T; Rosenberg SH; Lin NH J Med Chem; 2005 May; 48(9):3118-21. PubMed ID: 15857116 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. Li G; Hasvold LA; Tao ZF; Wang GT; Gwaltney SL; Patel J; Kovar P; Credo RB; Chen Z; Zhang H; Park C; Sham HL; Sowin T; Rosenberg SH; Lin NH Bioorg Med Chem Lett; 2006 Apr; 16(8):2293-8. PubMed ID: 16446090 [TBL] [Abstract][Full Text] [Related]
3. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464 [TBL] [Abstract][Full Text] [Related]
4. Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors. Tong Y; Claiborne A; Stewart KD; Park C; Kovar P; Chen Z; Credo RB; Gu WZ; Gwaltney SL; Judge RA; Zhang H; Rosenberg SH; Sham HL; Sowin TJ; Lin NH Bioorg Med Chem; 2007 Apr; 15(7):2759-67. PubMed ID: 17287122 [TBL] [Abstract][Full Text] [Related]
5. Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics. Tao ZF; Chen Z; Bui MH; Kovar P; Johnson E; Bouska J; Zhang H; Rosenberg S; Sowin T; Lin NH Bioorg Med Chem Lett; 2007 Dec; 17(23):6593-601. PubMed ID: 17935989 [TBL] [Abstract][Full Text] [Related]
6. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas. Oza V; Ashwell S; Almeida L; Brassil P; Breed J; Deng C; Gero T; Grondine M; Horn C; Ioannidis S; Liu D; Lyne P; Newcombe N; Pass M; Read J; Ready S; Rowsell S; Su M; Toader D; Vasbinder M; Yu D; Yu Y; Xue Y; Zabludoff S; Janetka J J Med Chem; 2012 Jun; 55(11):5130-42. PubMed ID: 22551018 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors. Wang L; Sullivan GM; Hexamer LA; Hasvold LA; Thalji R; Przytulinska M; Tao ZF; Li G; Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Merta P; Kovar P; Bouska JJ; Zhang H; Park C; Stewart KD; Sham HL; Sowin TJ; Rosenberg SH; Lin NH J Med Chem; 2007 Aug; 50(17):4162-76. PubMed ID: 17658776 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and in-vitro biological activity of macrocyclic urea Chk1 inhibitors. Li G; Tao ZF; Tong Y; Przytulinska MK; Kovar P; Merta P; Chen Z; Zhang H; Sowin T; Rosenberg SH; Lin NH Bioorg Med Chem Lett; 2007 Dec; 17(23):6499-504. PubMed ID: 17931867 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors. Tao ZF; Li G; Tong Y; Chen Z; Merta P; Kovar P; Zhang H; Rosenberg SH; Sham HL; Sowin TJ; Lin NH Bioorg Med Chem Lett; 2007 Aug; 17(15):4308-15. PubMed ID: 17544271 [TBL] [Abstract][Full Text] [Related]
10. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1. Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608 [TBL] [Abstract][Full Text] [Related]
11. Part II: New candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors. Galal SA; Khairat SHM; Ali HI; Shouman SA; Attia YM; Ali MM; Mahmoud AE; Abdel-Halim AH; Fyiad AA; Tabll A; El-Shenawy R; El Abd YS; Ramdan R; El Diwani HI Eur J Med Chem; 2018 Jan; 144():859-873. PubMed ID: 29316526 [TBL] [Abstract][Full Text] [Related]
12. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2. Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activities of new checkpoint kinase 1 inhibitors structurally related to granulatimide. Conchon E; Anizon F; Aboab B; Prudhomme M J Med Chem; 2007 Sep; 50(19):4669-80. PubMed ID: 17722905 [TBL] [Abstract][Full Text] [Related]
14. Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors. Teng M; Zhu J; Johnson MD; Chen P; Kornmann J; Chen E; Blasina A; Register J; Anderes K; Rogers C; Deng Y; Ninkovic S; Grant S; Hu Q; Lundgren K; Peng Z; Kania RS J Med Chem; 2007 Nov; 50(22):5253-6. PubMed ID: 17887663 [TBL] [Abstract][Full Text] [Related]
15. Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs. Galal SA; Abdelsamie AS; Shouman SA; Attia YM; Ali HI; Tabll A; El-Shenawy R; El Abd YS; Ali MM; Mahmoud AE; Abdel-Halim AH; Fyiad AA; Girgis AS; El-Diwani HI Eur J Med Chem; 2017 Jul; 134():392-405. PubMed ID: 28433679 [TBL] [Abstract][Full Text] [Related]
16. Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors. Tao ZF; Li G; Tong Y; Stewart KD; Chen Z; Bui MH; Merta P; Park C; Kovar P; Zhang H; Sham HL; Rosenberg SH; Sowin TJ; Lin NH Bioorg Med Chem Lett; 2007 Nov; 17(21):5944-51. PubMed ID: 17827013 [TBL] [Abstract][Full Text] [Related]
17. RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones. Lamie PF Bioorg Med Chem Lett; 2016 Jul; 26(13):3093-3097. PubMed ID: 27189674 [TBL] [Abstract][Full Text] [Related]
18. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α. Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891 [TBL] [Abstract][Full Text] [Related]
19. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. Reader JC; Matthews TP; Klair S; Cheung KM; Scanlon J; Proisy N; Addison G; Ellard J; Piton N; Taylor S; Cherry M; Fisher M; Boxall K; Burns S; Walton MI; Westwood IM; Hayes A; Eve P; Valenti M; de Haven Brandon A; Box G; van Montfort RL; Williams DH; Aherne GW; Raynaud FI; Eccles SA; Garrett MD; Collins I J Med Chem; 2011 Dec; 54(24):8328-42. PubMed ID: 22111927 [TBL] [Abstract][Full Text] [Related]
20. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells. Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]